- News & Events
- Professional Development
The Use of Disease-Modifying Therapies in Multiple Sclerosis: Principles and Current Evidence
The member organizations of the Multiple Sclerosis Coalition* have collaborated to summarize the current evidence about disease modification in multiple sclerosis (MS) and to provide support for broad access to U.S. Food and Drug Administration (FDA)-approved MS disease-modifying therapies for people. Endorsed by each of the seven MS Coalition organizations, this document serves as an evidence-based resource and reference tool for the clinical management of MS that may also be utilized in advocacy efforts to improve access to approved disease-modifying therapies for people living with MS.
*The Multiple Sclerosis Coalition (see p. 32), which was founded in 2005 to increase opportunities for cooperation and provide greater opportunity to leverage the effective use of resources for the benefit of the MS community, includes Accelerated Cure Project for Multiple Sclerosis, Can Do Multiple Sclerosis, Consortium of Multiple Sclerosis Centers, International Organization of Multiple Sclerosis Nurses, Multiple Sclerosis Association of America, Multiple Sclerosis Foundation, National Multiple Sclerosis Society and the United Spinal Association.
Purpose: The purpose of this paper, which was developed by the member organizations of the Multiple Sclerosis Coalition, is to summarize current evidence about disease modification in multiple sclerosis (MS) and provide support for broad and sustained access to MS disease-modifying therapies for people with MS in the United States.